<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>liver transplantation &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/liver-transplantation/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 24 Jan 2026 18:11:07 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>liver transplantation &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>NK Cell Infusion Shows Promise in Liver Cancer Trial</title>
		<link>https://bioengineer.org/nk-cell-infusion-shows-promise-in-liver-cancer-trial/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 24 Jan 2026 18:10:47 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[**Uygun Etiketler:** Hepatocellular carcinoma]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[Hepatocellular Carcinoma]]></category>
		<category><![CDATA[immunotherapy]]></category>
		<category><![CDATA[liver transplantation]]></category>
		<category><![CDATA[Liver transplantation recurrence]]></category>
		<category><![CDATA[NK cell therapy]]></category>
		<category><![CDATA[Phase I trial]]></category>
		<guid isPermaLink="false">https://bioengineer.org/nk-cell-infusion-shows-promise-in-liver-cancer-trial/</guid>

					<description><![CDATA[In a remarkable advancement in the field of oncology, particularly in the treatment of hepatocellular carcinoma (HCC), recent research has shed light on the potential of Natural Killer (NK) cell infusion therapy for patients who have faced recurrent cancers post-liver transplantation. This groundbreaking phase I trial, led by researchers including Yang, F., Gong, Y., and [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">320397</post-id>	</item>
		<item>
		<title>Liver Transplants Using Grafts from Medically Assisted Death Donors Show Feasibility and Comparable Outcomes to Standard Donations</title>
		<link>https://bioengineer.org/liver-transplants-using-grafts-from-medically-assisted-death-donors-show-feasibility-and-comparable-outcomes-to-standard-donations/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 27 Oct 2025 04:21:01 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Donor graft viability]]></category>
		<category><![CDATA[liver transplantation]]></category>
		<category><![CDATA[Medical assistance in dying (MAiD)]]></category>
		<category><![CDATA[Organ donor pool expansion]]></category>
		<category><![CDATA[Transplantation ethics]]></category>
		<guid isPermaLink="false">https://bioengineer.org/liver-transplants-using-grafts-from-medically-assisted-death-donors-show-feasibility-and-comparable-outcomes-to-standard-donations/</guid>

					<description><![CDATA[In recent years, medical advances have increasingly embraced practices that push the boundaries of traditional organ donation protocols. A groundbreaking study published in the Journal of Hepatology explores the clinical outcomes and feasibility of liver transplantation using grafts obtained from donors who underwent medical assistance in dying (MAiD). This emerging approach, also known as euthanasia [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">287060</post-id>	</item>
		<item>
		<title>Early Proteomic Insights into Acute Kidney Injury Post-Liver Transplant</title>
		<link>https://bioengineer.org/early-proteomic-insights-into-acute-kidney-injury-post-liver-transplant/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 25 Oct 2025 11:22:19 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[acute kidney injury]]></category>
		<category><![CDATA[Acute Kidney Injury Post-Liver Transplant]]></category>
		<category><![CDATA[Early AKI Detection Strategies]]></category>
		<category><![CDATA[Inflammatory Cascade in Renal Injury]]></category>
		<category><![CDATA[inflammatory response]]></category>
		<category><![CDATA[liver transplantation]]></category>
		<category><![CDATA[Precision Medicine]]></category>
		<category><![CDATA[Precision Medicine in Organ Transplantation]]></category>
		<category><![CDATA[proteomic analysis]]></category>
		<category><![CDATA[Proteomic Biomarkers in Transplantation]]></category>
		<guid isPermaLink="false">https://bioengineer.org/early-proteomic-insights-into-acute-kidney-injury-post-liver-transplant/</guid>

					<description><![CDATA[The realm of regenerative medicine frequently thrives on the intricate interplay between organ systems, unveiling a cascade of biochemical and physiological responses that occur during organ transplantation. A recent commentary by Chen and Luo has attracted considerable attention in the medical community for its far-reaching implications in understanding acute kidney injury (AKI) following liver graft [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">286782</post-id>	</item>
	</channel>
</rss>
